---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-022830"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:20:02.014947+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TransCode acquires exclusive license to oncolytic immunotherapy platform in all-stock deal

## Summary
- Issued 1,136,364 shares of Series C non-voting convertible preferred to Unleash; convertible to common after stockholder approval.
- Preferred stock represents 6.8% of TransCode's fully diluted common stock.
- Lead candidate UIO-524 targets muscle-invasive bladder cancer (MIBC), a high-unmet-need indication.
- License is exclusive, worldwide, fully paid-up, royalty-free; no future cash payments.
- Tungsten Advisors received 77,841 Series C shares as financial advisor compensation.

## SEC filing metadata
- accession: 0001104659-26-022830
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.02, 8.01, 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465926022830/0001104659-26-022830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465926022830/tm267831d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-022830
- JSON: https://secwatch.observer/filing/0001104659-26-022830.json
- Plain text: https://secwatch.observer/filing/0001104659-26-022830.txt

## Source-grounded claims
- claim_id: 3ab96d37f9fabd5f7d738c9421b5e54759658ea9
  claim: Transcode Therapeutics, Inc.: Filed Certificate of Designation for Series C Non-Voting Convertible Preferred Stock, establishing its preferences, rights, and limitations (effective 2026-03-02).
  evidence_excerpt: On March 2, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) of the Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the “Series C Preferred Stock”) with the Secretary of State of the State of Delaware
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465926022830/0001104659-26-022830-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.